Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
Conditions
- Non-Alcoholic Fatty Liver Disease
- Hyperuricemia
Interventions
- DRUG: Allopurinol (100 mg/day) plus lifestyle intervention
- DRUG: Febuxostat 40 mg plus lifestyle intervention
- BEHAVIORAL: Life style intervention
Sponsor
Ain Shams University